Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + vincristine + prednisone + dacarbazine
- Development stage
- Phase 3
- Lead developer
- National Cancer Institute
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A multi-agent chemotherapy regimen consisting of cyclophosphamide, vincristine, prednisone, and dacarbazine. It is primarily utilized in the treatment of Hodgkin lymphoma, particularly in pediatric or relapsed/refractory settings, and has been investigated for neuroblastoma. Cyclophosphamide and dacarbazine act as alkylating agents that damage DNA, vincristine inhibits microtubule formation to arrest mitosis, and prednisone provides lympholytic effects and reduces inflammation.
- Brand names
- COPDAC-28COPDAC28COPDAC 28
- Other names
- CVPDCVPD regimen
02
Targets
DNAGR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cyclophosphamide + vincristine + prednisone + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + vincristine + prednisone + dacarbazine.